Cefiderocol for treatment of complicated urinary tract infections

Affiliations

¹ Shionogi Inc, Florham Park, NJ, USA. Electronic address: simon.portsmouth@shionogi.com.
² ID3C, Easton, CT, USA.
³ Shionogi & Co Ltd, Osaka, Japan.

Comment

Simon Portsmouth et al. Lancet Infect Dis. 2019 Jan.

. 2019 Jan;19(1):23-24.

doi: 10.1016/S1473-3099(18)30721-7.

¹ Shionogi Inc, Florham Park, NJ, USA. Electronic address: simon.portsmouth@shionogi.com.
² ID3C, Easton, CT, USA.
³ Shionogi & Co Ltd, Osaka, Japan.

No abstract available

Comment in

Cefiderocol for treatment of complicated urinary tract infections - Author's reply.
Huttner A. Huttner A. Lancet Infect Dis. 2019 Jan;19(1):24-25. doi: 10.1016/S1473-3099(18)30728-X. Lancet Infect Dis. 2019. PMID: 30587291 No abstract available.

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira JCA, Ariyasu M, Tenke P, Nagata TD. Portsmouth S, et al. Lancet Infect Dis. 2018 Dec;18(12):1319-1328. doi: 10.1016/S1473-3099(18)30554-1. Epub 2018 Oct 25. Lancet Infect Dis. 2018. PMID: 30509675 Clinical Trial.